PCM
IMGN

Palisade Capital Management’s Immunogen Inc IMGN Stock Holding History

Palisade Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,500
Closed -$80K – 465
2017
Q4 		$80K Buy
12,500
+200
+2% +$1.23K ﹤0.01% 431
2017
Q3 		$94K Buy
+12,300
New +$81.7K ﹤0.01% 431
2017
Q1 		– Sell
-12,600
Closed -$26K – 472
2016
Q4 		$26K Buy
+12,600
New +$25.3K ﹤0.01% 455

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Palisade Capital Management's IMGN Position: Q1 2018 in Review

Palisade Capital Management sold out of Immunogen Inc (IMGN) in Q1 2018, closing a stake of 12,500 shares — an estimated $80K sold.

Palisade Capital Management first reported a position in IMGN in Q4 2016 and held it in 3 quarters. The position peaked at $94K in Q3 2017. 204 funds tracked by Wall St. Rank hold IMGN as of Q1 2018.

  • Palisade Capital Management reported no remaining Immunogen Inc position as of Q1 2018 after selling out during the quarter.
  • Palisade Capital Management sold 12,500 Immunogen Inc shares in Q1 2018, an estimated $80K.
  • Palisade Capital Management first reported a position in Immunogen Inc in Q4 2016 and held it in 3 quarters.
  • Palisade Capital Management's Immunogen Inc position peaked at $94K in Q3 2017.
  • 204 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2018.

Based on Palisade Capital Management's 13F filing for Q1 2018, filed 9 May 2018.